One of the useful features pointing to ''BRCA1-ness'' appeared to be high expression of the epidermal growth factor receptor (EGFR). No rationale is given by the authors for including EGFR in the analysis. There is a clear one, however: EGF (likely acting through EGFR) was related to the basal phenotype in breast cancer by DiRenzo et al. (2). Furthermore, the finding of high EGFR expression in BRCA1-related breast cancer confirms previous data from our published study (3). We examined EGFR expression by immunohistochemistry in the invasive breast cancers from 21 proven carriers of BRCA1 germ line mutations, as well as from a control group of 430 invasive breast cancers from patients unselected for a family history of breast cancer. Of the 21 BRCA1-related breast cancers, 14 (67%) showed EGFR overexpression. In the control group of 430 tumors, EGFR overexpression was found in only 70 (16%) (P < 0.001, two-sided Fisher's exact test). Also, the full ERÀ/erbB2À/EGFR+ phenotype was statistically significantly more frequent in BRCA1 mutation carriers (P < 0.001).
To the Editor: In their article, Lakhani et al. (1) report on the value of basal phenotype markers for the prediction of BRCA1 status. One of the useful features pointing to ''BRCA1-ness'' appeared to be high expression of the epidermal growth factor receptor (EGFR). No rationale is given by the authors for including EGFR in the analysis. There is a clear one, however: EGF (likely acting through EGFR) was related to the basal phenotype in breast cancer by DiRenzo et al. (2) . Furthermore, the finding of high EGFR expression in BRCA1-related breast cancer confirms previous data from our published study (3) . We examined EGFR expression by immunohistochemistry in the invasive breast cancers from 21 proven carriers of BRCA1 germ line mutations, as well as from a control group of 430 invasive breast cancers from patients unselected for a family history of breast cancer. Of the 21 BRCA1-related breast cancers, 14 (67%) showed EGFR overexpression. In the control group of 430 tumors, EGFR overexpression was found in only 70 (16%) (P < 0.001, two-sided Fisher's exact test). Also, the full ERÀ/erbB2À/EGFR+ phenotype was statistically significantly more frequent in BRCA1 mutation carriers (P < 0.001).
We hypothesize that this EGFR overexpression is probably largely posttranscriptionally regulated, as amplification of the EGFR gene seems to be very rare in invasive breast cancer (4), gains at the EGFR locus were not observed by comparative genomic hybridization (5), and increased EGFR mRNA expression was not observed in two gene expression studies in hereditary breast cancer (6, 7). We therefore urge further investigation into the mechanisms of EGFR overexpression in hereditary breast cancer and into new preventive strategies through EGFR targeting.
As the first article relating EGFR to the basal phenotype and the previously published EGFR expression results in BRCA1-related breast cancer were not referred to, and mechanisms behind the interesting finding of high EGFR expression in BRCA1-related breast cancer were not discussed, we would like to bring this to the attention of the Clinical Cancer Research readership.
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